Gene Biotherapeutics (CRXM) Short Interest Ratio & Short Volume → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free CRXM Stock Alerts Add Compare Share Share Short InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Gene Biotherapeutics Short Interest DataCurrent Short Interest100 sharesPrevious Short Interest100 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$0.00Short Interest Ratio0.1 Days to CoverLast Record DateMay 15, 2024Today's Trading Volume0 sharesAverage Trading Volume0 sharesToday's Volume Vs. AverageNaN Short Selling Gene Biotherapeutics ? Sign up to receive the latest short interest report for Gene Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCRXM Short Interest Over TimeCRXM Days to Cover Over TimeCRXM Percentage of Float Shorted Over Time Ad Weiss RatingsWhat is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners”A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. Gene Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2024100 shares $0.00 No ChangeN/A0.1 $0.00 4/30/2024100 shares $0.00 No ChangeN/A1 $0.00 4/15/2024100 shares $0.00 No ChangeN/A0 $0.00 3/31/2024100 shares $0.00 No ChangeN/A0 $0.00 3/15/2024100 shares $0.00 No ChangeN/A0 $0.00 2/29/2024100 shares $0.00 No ChangeN/A0 $0.00 Get the Latest News and Ratings for CRXM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gene Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024100 shares $0.00 No ChangeN/A1 $0.00 1/15/2024100 shares $0.00 No ChangeN/A0 $0.00 12/31/2023100 shares $0.00 No ChangeN/A0 $0.00 12/15/2023100 shares $0.00 No ChangeN/A0 $0.00 11/30/2023100 shares $0.00 No ChangeN/A0.2 $0.00 11/15/2023100 shares $0.00 No ChangeN/A0 $0.00 10/31/2023100 shares $0.00 No ChangeN/A0 $0.00 10/15/2023100 shares $0.00 No ChangeN/A0 $0.00 9/30/2023100 shares $0.00 No ChangeN/A1 $0.00 9/15/2023100 shares $0.00 No ChangeN/A0 $0.00 8/31/2023100 shares $0.00 No ChangeN/A49.5 $0.00 8/15/2023100 shares $0.00 No ChangeN/A1 $0.00 7/31/2023100 shares $0.00 No ChangeN/A0.1 $0.00 7/15/2023100 shares $0.00 No ChangeN/A0 $0.00 6/30/2023100 shares $0.00 No ChangeN/A0 $0.00 6/15/2023100 shares $0.00 No ChangeN/A0 $0.00 5/31/2023100 shares $0.00 No ChangeN/A1 $0.00 5/15/2023100 shares $0.00 No ChangeN/A0.5 $0.00 4/30/2023100 shares $0.00 No ChangeN/A0.1 $0.00 4/15/2023100 shares $0.00 No ChangeN/A0 $0.00 3/31/2023100 shares $0.00 No ChangeN/A1 $0.00 3/15/2023100 shares $0.00 No ChangeN/A0 $0.00 2/28/2023100 shares $0.00 No ChangeN/A0 $0.00 2/15/2023100 shares $0.00 No ChangeN/A1 $0.00 1/31/2023100 shares $0.00 No ChangeN/A1 $0.00 1/15/2023100 shares $0.00 No ChangeN/A0 $0.00 12/30/2022100 shares $0.00 No ChangeN/A0 $0.00 12/15/2022100 shares $0.00 No ChangeN/A0 $0.00 11/30/2022100 shares $0.00 No ChangeN/A1 $0.00 11/15/2022100 shares $0.00 No ChangeN/A0 $0.00 10/31/2022100 shares $0.00 No ChangeN/A0 $0.00 10/15/2022100 shares $0.00 No ChangeN/A1 $0.00 9/30/2022100 shares $0.00 No ChangeN/A0 $0.00 9/15/2022100 shares $0.00 No ChangeN/A1 $0.00The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. 8/31/2022100 shares $0.00 No ChangeN/A1 $0.00 8/15/2022100 shares $0.00 No ChangeN/A0.1 $0.00 7/31/2022100 shares $0.00 No ChangeN/A0.3 $0.00 7/15/2022100 shares $0.00 No ChangeN/A0 $0.00 6/30/2022100 shares $0.00 No ChangeN/A0.3 $0.00 6/15/2022100 shares $0.00 No ChangeN/A1 $0.00 5/31/2022100 shares $0.00 No ChangeN/A0 $0.00 5/15/2022100 shares $0.00 No ChangeN/A0 $0.00 4/30/2022100 shares $0.00 No ChangeN/A1 $0.00 4/15/2022100 shares $0.00 No ChangeN/A0.3 $0.00 3/31/2022100 shares $0.00 No ChangeN/A0 $0.00 3/15/2022100 shares $0.00 No ChangeN/A0.3 $0.00 2/28/2022100 shares $0.00 No ChangeN/A1 $0.00 2/15/2022100 shares $0.00 No ChangeN/A0 $0.00 1/31/2022100 shares $0.00 No ChangeN/A0 $0.00 1/15/2022100 shares $0.00 No ChangeN/A0 $0.00 12/31/2021100 shares $0.00 No ChangeN/A0.3 $0.00 12/15/2021100 shares $0.00 No ChangeN/A0 $0.00 11/30/2021100 shares $0.00 No ChangeN/A0.2 $0.00 11/15/2021100 shares $0.01 No ChangeN/A0 $0.00 10/29/2021100 shares $0.09 No ChangeN/A0 $0.00 10/15/2021100 shares $3.30 No ChangeN/A0 $0.03 9/30/2021100 shares $3.30 -99.4%N/A0 $0.03 9/15/202115,600 shares $600.60 -80.7%N/A0 $0.04 8/31/202180,600 shares $3,457.74 +406.9%N/A0.2 $0.04 8/13/202115,900 shares $704.37 -29.0%N/A0 $0.04 7/30/202122,400 shares $1,220.80 -36.4%N/A0 $0.05 7/15/202135,200 shares $1,760.00 +235.2%N/A0 $0.05 6/30/202110,500 shares $483.00 -70.8%N/A0 $0.05 6/15/202135,900 shares $1,787.82 -56.3%N/A0 $0.05 5/28/202182,100 shares $3,940.80 +269.8%N/A0.1 $0.05 5/14/202122,200 shares $1,110.00 +58.6%N/A0 $0.05 4/30/202114,000 shares $840.00 +241.5%N/A0 $0.06 4/15/20214,100 shares $164.00 -90.6%N/A0 $0.04 3/31/202143,700 shares $2,359.80 +43,600.0%N/A0 $0.05 3/15/2021100 shares $4.00 -99.9%N/A0 $0.04 2/26/202199,200 shares $4,464.00 +6.2%N/A0.1 $0.05 2/12/202193,400 shares $4,903.50 +613.0%N/A0.2 $0.05 1/29/202113,100 shares $524.00 +21.3%N/A0 $0.04 1/15/202145,500 shares $1,820.00 +135.8%N/A0.1 $0.04 12/31/202015,200 shares $577.60 -66.6%N/A0 $0.04 12/15/202045,500 shares $1,820.00 +135.8%N/A0.1 $0.04 11/30/202019,300 shares $733.40 -16.1%N/A0 $0.04 11/15/202023,000 shares $1,207.50 +22,900.0%N/A0.1 $0.05 10/30/2020100 shares $6.05 -99.8%N/A0 $0.06 10/15/202050,200 shares $3,012.00 +241.5%N/A0.1 $0.06 9/30/202014,700 shares $918.75 -43.0%N/A0 $0.06 9/15/202025,800 shares $2,322.00 -48.0%N/A0 $0.09 8/31/202049,600 shares $3,224.00 +49,500.0%N/A0.1 $0.07 8/14/2020100 shares $7.25 -99.8%N/A0 $0.07The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. 7/31/202062,300 shares $4,984.00 +74.5%N/A0.1 $0.08 7/15/202035,700 shares $3,002.37 -40.4%N/A0 $0.08 6/30/202059,900 shares $2,246.25 +57.6%N/A0.6 $0.04 6/15/202038,000 shares $1,520.00 +103.2%N/A0.2 $0.04 5/29/202018,700 shares $2,765.73 +12.0%N/A0.4 $0.15 5/15/202016,700 shares $2,474.94 +328.2%N/A1.1 $0.15 4/30/20203,900 shares $579.54 +3,800.0%N/A0.1 $0.15 4/15/2020100 shares $15.90 No ChangeN/A0 $0.16 3/31/2020100 shares $15.00 No ChangeN/A0 $0.15 3/13/2020100 shares $15.00 No ChangeN/A0 $0.15 2/28/2020100 shares $16.00 No ChangeN/A0 $0.16 2/14/2020100 shares $16.00 No ChangeN/A0.1 $0.16 1/31/2020100 shares $16.00 No ChangeN/A0 $0.16 1/15/2020100 shares $17.00 -50.0%N/A0 $0.17 12/31/2019200 shares $30.00 +100.0%N/A0 $0.15 CRXM Short Interest - Frequently Asked Questions What is Gene Biotherapeutics' current short interest? Short interest is the volume of Gene Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 100 shares of CRXM short. Learn More on Gene Biotherapeutics' current short interest. How does Gene Biotherapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Gene Biotherapeutics: Amgen Inc. (1.92%), Gilead Sciences, Inc. (1.75%), Moderna, Inc. (6.36%), Biogen Inc. (2.41%), Novozymes A/S (0.00%), argenx SE (2.25%), BioNTech SE (1.44%), Neurocrine Biosciences, Inc. (1.85%), Qiagen (1.39%), Repligen Co. (8.38%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Gene Biotherapeutics stock? Short selling CRXM is an investing strategy that aims to generate trading profit from Gene Biotherapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Gene Biotherapeutics? A short squeeze for Gene Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRXM, which in turn drives the price of the stock up even further. How often is Gene Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRXM, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: CORC Short Squeeze QNNTF Short Squeeze TNGNQ Short Squeeze AMGN Short Squeeze GILD Short Squeeze MRNA Short Squeeze BIIB Short Squeeze NVZMY Short Squeeze ARGX Short Squeeze BNTX Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:CRXM) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gene Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.